FDA review highlights expanding role of manufacturing process models in drug applications

The FDA released a review outlining how manufacturers can incorporate process modeling into their regulatory submissions.

Process models are described as a growing scientific area and are being used more frequently in new drug applications, biologics license applications, and supplemental filings.

The agency’s guidance highlights the benefits of using these models to support manufacturing consistency and product quality, and it signals that regulators expect broader adoption in future submissions.